Physician profile
Ruby Renee Leach
NPI 1376637942
$5,001.11
in general payments reported to CMS, 2019-2025
32 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $386 · 2023: $1,326 · 2024: $1,286 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $762.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $678.40 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $502.79 | 2021-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $461.87 | 2021-2025 | |
| Novo Nordisk INC | $358.42 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $312.22 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Xeris Pharmaceuticals, INC. | $293.21 | 2022-2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $187.66 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.49 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $143.83 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.11 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $114.60 | 2024-2025 | |
| Glaxosmithkline, LLC. | $113.94 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $91.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $81.95 | 2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $75.48 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $73.14 | 2022-2025 | Fanapt |
| Gilead Sciences, INC. | $55.35 | 2025 | |
| Axsome Therapeutics, INC. | $51.05 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.33 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $42.68 | 2024-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $41.48 | 2021-2025 | Elaprase |
| Dexcom, INC. | $39.38 | 2021-2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $37.50 | 2022-2024 | Heplisav-B |
| Insulet Corporation | $34.84 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $26.64 | 2024 | Ajovy |
| Tris Pharma INC | $20.41 | 2025 | Dyanavel Xr |
| Azurity Pharmaceuticals, INC. | $16.01 | 2025 | Edarbi |
| Ultragenyx Pharmaceutical INC. | $15.07 | 2022 | |
| Corium, LLC | $15.04 | 2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2025 | Zoryve |
| Eisai INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.